Dr Mark Lebwohl provided insights into the use of dupilumab for treating prurigo nodularis. He also elaborated on the characteristics of generalized pustular psoriasis and the effectiveness of treatments such as systemic corticosteroids, folic acid antagonists, and spesolimab. Spesolimab infusions, Dr Lebwohl noted, can also benefit patients with pyoderma gangrenosum, citing several severe cases that showed improvement with this therapy. Additionally, he shared therapeutic tips for managing dermatoses associated with ACE inhibitors, including pruritis and angioedema.

Chronic pruritis is notoriously challenging to treat, and new therapies are under investigation for their effectiveness. Dr Lebwohl discussed the utility of dupilumab and nemolizumab for this condition. Furthermore, he provided clinical insights into treating various skin conditions: upadacitinib for erosive lichen planus, tofacitinib for lichen planopilaris, and oral ruxolitinib for chronic spontaneous urticaria, among others.